The opioid overdose crisis has brought significant regulatory changes throughout the country to how, when, and why prescribers may write opioid prescriptions. In Louisiana, new laws are in place requiring education on prescribing controlled substances to proactively curb opioid abuse:
- Each prescriber must now complete three hours of education on drug diversion, prescribers' best practices and addiction treatment.
- The required education must be completed before license renewal in 2019 or upon initial licensure.
- This new education requirement is included in the credit hours already required by the Louisiana State Board of Medical Examiners (LSBME), not in addition to the existing requirements.
LAMMICO, in partnership with the Louisiana State Medical Society (LSMS), has developed a three-hour controlled substance course to meet the new Louisiana state requirements. The course for Louisiana providers is titled "Louisiana Act 76, Controlled Substances: Prescribing, Diversion Prevention and Addiction Treatment". This course meets the subject requirements specified by Act 76 of the Louisiana Legislature and the LSBME's rules. With permission, LAMMICO can also report completion of the course to the LSBME. In addition to meeting state requirements, this course also provides three (3) contact hours for CME, CNE, MOC, AAPA and AANP (includes pharmacology credit) and one (1) LAMMICO Risk Management Premium Discount Credit.
LAMMICO policyholders may access the course free of charge by logging in as a Member at lammico.com. Members of the LSMS who are not LAMMICO insureds may also access the course free of charge by logging in to the LSMS website at lsms.org.
Louisiana healthcare providers that are neither LAMMICO insureds nor members of the LSMS may take the course for a fee through LAMMICO's subsidiary risk management education company, Medical Interactive Community, at medicalinteractive.net. Groups of 20 or more providers that are interested in purchasing this education at a discounted price should contact Robbi Quigley, Account Executive, at 504.841.5281 or 844.923.9899.
Also in the new law, there is a provision about the Louisiana Prescription Monitoring Program (PMP). Upon initial application or renewal of a controlled dangerous substance license by the Board of Pharmacy, a controlled substance prescriber will be automatically registered in the PMP. Providers who are registered with and utilize the PMP may be able to avoid a penalty in the Quality Payment Program for 2017 and 2018. For guidance on this or other QPP reporting, contact LAMMICO Practice Management Specialist, Natalie Cohen, at email@example.com or 504.841.2427.
LAMMICO is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. LAMMICO designates this online enduring activity for a maximum of three (3) AMA PRA Category 1 Credit(s)™.
This continuing nursing education program has been approved for 3 contact hours by LAMMICO/Medical Interactive. LAMMICO/Medical Interactive is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This activity is approved for 3.0 contact hour(s) of continuing education (which includes 3.0 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID 18023068. This activity was planned in accordance with AANP CE Standards and Policies.
This program has been reviewed and is approved for a maximum of 3.00 AAPA Category 1 CME credits by the AAPA Review Panel. Approval is valid for one year from the issue date of 03/05/2018. Participants may submit the post-test at any time during that period.